Evidence map›Paper›PMID 40994640›Full record

ArticleFrontiers in pharmacology2025

S B Martins, S C Teixeira, G de Souza, Bader Y Alhatlani, Emad M Abdallah, S R Ambrosio, T S Silva, J K Bastos, M H Tanimoto, B F Barbosa and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Zoliflodacin inhibitsFrontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

S B MartinsLaboratory of Antimicrobial Testing, Institute of Biomedical Sciences, Federal University of Uberlândia - UFU, Uberlândia, Minas Gerais, Brazil.
S C TeixeiraLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Sciences, Federal University of Uberlândia - UFU, Uberlândia, Minas Gerais, Brazil.
G de SouzaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Sciences, Federal University of Uberlândia - UFU, Uberlândia, Minas Gerais, Brazil.
Bader Y AlhatlaniUnit of Scientific Research, Applied College, Qassim University, Buraydah, Saudi Arabia.
Emad M AbdallahDepartment of Biology, College of Science, Qassim University, Buraydah, Saudi Arabia.
S R AmbrosioNucleus of Research in Technological and Exact Sciences, University of Franca - UNIFRAN, São Paulo, Brazil.
T S SilvaUnit of Scientific Research, Applied College, Qassim University, Buraydah, Saudi Arabia.
J K BastosSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo - USP, São Paulo, Brazil.
M H TanimotoSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo - USP, São Paulo, Brazil.
B F BarbosaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Sciences, Federal University of Uberlândia - UFU, Uberlândia, Minas Gerais, Brazil.
E A V FerroLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Sciences, Federal University of Uberlândia - UFU, Uberlândia, Minas Gerais, Brazil.
C H G MartinsLaboratory of Antimicrobial Testing, Institute of Biomedical Sciences, Federal University of Uberlândia - UFU, Uberlândia, Minas Gerais, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis persists as a major global health threat and remains the leading cause of death from infectious disease. Efforts to control the disease are increasingly hampered by the emergence of drug-resistant Methods: This study evaluated the Results: CHEBRP exhibited potent activity against most Conclusion: These

Indexed as

antibacterial activityantibiofilmanti-tuberculousBrazilian red propolishealth

Identifiers

PMID40994640
PMCPMC12455237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.